These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38112286)

  • 1. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.
    Voskamp AL; Khosa S; Phan T; DeBerg HA; Bingham J; Hew M; Smith W; Abramovitch J; Rolland JM; Moyle M; Nadeau KC; Lack G; Larché M; Wambre E; O'Hehir RE; Hickey P; Prickett SR
    Allergy; 2024 Feb; 79(2):485-498. PubMed ID: 38112286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
    Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AR101 Oral Immunotherapy for Peanut Allergy.
    ; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
    N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results.
    Pongracic JA; Gagnon R; Sussman G; Siri D; Oriel RC; Brown-Whitehorn TF; Green TD; Campbell DE; Anvari S; Berger WE; Bird JA; Chan ES; Cheema A; Chinthrajah RS; Chong HJ; Dowling PJ; Fineman SM; Fleischer DM; Gonzalez-Reyes E; Kim EH; Lanser BJ; MacGinnitie A; Mehta H; Petroni D; Rupp N; Schneider LC; Scurlock AM; Sher LD; Shreffler WG; Sindher SB; Stillerman A; Wood R; Yang WH; Bois T; Sampson HA; Bégin P
    J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1864-1873.e10. PubMed ID: 34848381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
    Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
    Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts.
    Berin MC; Agashe C; Burks AW; Chiang D; Davidson WF; Dawson P; Grishin A; Henning AK; Jones SM; Kim EH; Leung DYM; Masilamani M; Scurlock AM; Sicherer SH; Wood RA; Sampson HA
    J Allergy Clin Immunol; 2022 Apr; 149(4):1373-1382.e12. PubMed ID: 34653515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
    Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW;
    J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
    Greenhawt M; Sindher SB; Wang J; O'Sullivan M; du Toit G; Kim EH; Albright D; Anvari S; Arends N; Arkwright PD; Bégin P; Blumchen K; Bourrier T; Brown-Whitehorn T; Cassell H; Chan ES; Ciaccio CE; Deschildre A; Divaret-Chauveau A; Dorris SL; Dorsey MJ; Eiwegger T; Erlewyn-Lajeunesse M; Fleischer DM; Ford LS; Garcia-Lloret M; Giovannini-Chami L; Hourihane JO; Jay N; Jones SM; Kerns LA; Kloepfer KM; Leonard S; Lezmi G; Lieberman JA; Lomas J; Makhija M; Parrish C; Peake J; Perrett KP; Petroni D; Pfützner W; Pongracic JA; Quinn P; Robison RG; Sanders G; Schneider L; Sharma HP; Trujillo J; Turner PJ; Tuttle K; Upton JE; Varshney P; Vickery BP; Vogelberg C; Wainstein B; Wood RA; Bee KJ; Campbell DE; Green TD; Rouissi R; Peillon A; Bahnson HT; Bois T; Sampson HA; Burks AW
    N Engl J Med; 2023 May; 388(19):1755-1766. PubMed ID: 37163622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
    Ciaccio C; Goldsobel AB; Anagnostou A; Beyer K; Casale TB; Deschildre A; Fernández-Rivas M; Hourihane JO; Krawiec M; Lieberman J; Scurlock AM; Vickery BP; Smith A; Tilles SA; Adelman DC; Brown KR;
    Ann Allergy Asthma Immunol; 2022 Dec; 129(6):758-768.e4. PubMed ID: 35973655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
    Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study).
    Fauquert JL; Michaud E; Pereira B; Bernard L; Gourdon-Dubois N; Rouzaire PO; Rochette E; Merlin E; Evrard B;
    Clin Exp Allergy; 2018 Jul; 48(7):862-874. PubMed ID: 29665158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.
    Bajzik V; DeBerg HA; Garabatos N; Rust BJ; Obrien KK; Nguyen QA; O'Rourke C; Smith A; Walker AH; Quinn C; Gersuk VH; Farrington M; Jeong D; Vickery BP; Adelman DC; Wambre E
    Allergy; 2022 Aug; 77(8):2534-2548. PubMed ID: 35266148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immunotherapy using boiled peanuts for treating peanut allergy: An open-label, single-arm trial.
    Grzeskowiak LE; Tao B; Aliakbari K; Chegeni N; Morris S; Chataway T
    Clin Exp Allergy; 2023 Mar; 53(3):327-336. PubMed ID: 36628520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.
    Brown KR; Baker J; Vereda A; Beyer K; Burks AW; du Toit G; O'B Hourihane J; Jones SM; Norval D; Dana A; Shreffler W; Vickery BP; Casale T; Skeel B; Adelman D
    J Allergy Clin Immunol; 2022 Jun; 149(6):2043-2052.e9. PubMed ID: 34971646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
    Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial.
    Michaud E; Evrard B; Pereira B; Rochette E; Bernard L; Rouzaire PO; Gourdon-Dubois N; Merlin E; Fauquert JL
    Trials; 2015 Apr; 16():197. PubMed ID: 25925398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice.
    Kulis M; Chen X; Lew J; Wang Q; Patel OP; Zhuang Y; Murray KS; Duncan MW; Porterfield HS; W Burks A; Dreskin SC
    Clin Exp Allergy; 2012 Feb; 42(2):326-36. PubMed ID: 22288514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.